<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313078</url>
  </required_header>
  <id_info>
    <org_study_id>100028</org_study_id>
    <secondary_id>10-C-0028</secondary_id>
    <nct_id>NCT01313078</nct_id>
  </id_info>
  <brief_title>Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer</brief_title>
  <official_title>Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - The best treatment for ovarian and related female reproductive tract cancers is not yet
      known for patients whose disease has not responded to or has recurred after standard
      treatment. The cancer treatment drug pegaspargase (ONCASPAR (Trademark)), which works
      differently from standard chemotherapy, has been approved to treat leukemia and has been
      given to a small number of patient with ovarian and other types of cancer. Because
      pegaspargase may reduce the development of cancer cells and blood vessel cells that
      contribute to cancer growth and ability to spread, treatment with pegaspargase could shrink
      ovarian cancer tumors and help ovarian cancer patients live longer and with fewer symptoms
      from their disease.

      Objectives:

      - To evaluate the safety and effectiveness of pegaspargase in patients with recurrent or
      refractory ovarian cancer, fallopian tube cancer, and/or primary peritoneal cancer.

      Eligibility:

      - Women at least 18 years of age who have been diagnosed with epithelial ovarian cancer,
      fallopian tube cancer, or primary peritoneal cancer that has not responded to at least one
      operation, chemotherapy, and/or radiotherapy.

      Design:

        -  Before the start of the study, participants will be screened with a medical history,
           blood tests, imaging scans of the affected areas, tumor biopsies, and other tests as
           directed by the study doctors.

        -  Participants will receive an infusion of pegaspargase on Day 1 and Day 15 of each 28-day
           cycle.

        -  Participants will have dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at
           the start of the study, before beginning pegaspargase, and again 6 weeks into the
           treatment. This test will determine if pegaspargase is affecting blood flow to the
           cancer site.

        -  Participants will have a computed tomography scan or other imaging every other cycle
           (approximately every 8 weeks) to determine whether the therapy is affecting the cancer
           site.

        -  The treatment will be repeated as long as the participant tolerates the medication and
           his or her cancer is either steady or improving.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  The bacterial enzyme L-asparaginase (L-ASP) catalyzes hydrolysis of asparagine to
           aspartate and is used to treat acute lymphoblastic leukemia (ALL).Studies demonstrated
           in vitro cytotoxic activity against solid tumor types including ovarian cancer.

        -  Our laboratory demonstrated L-ASP inhibits vascular remodeling and modulates heterotypic
           adhesion interactions between ovarian cancer cells and endothelial cells. Results
           indicate L-ASP has the ability to modify the local tumor microenvironment.

        -  Epithelial ovarian cancer requires neovascularization for growth and metastasis.
           Anti-angiogenesis agents show promise in treatment of recurrent disease.

        -  The pegylated form of L-ASP, pegaspargase, (Sigma Tau ONCASPAR (Trademark)) is shown to
           deplete serum levels of asparagine and is approved for ALL. ONCASPAR is in clinical
           trial with gemcitabine for pancreatic cancer and other solid tumors.

        -  Recommended dose of pegaspargase in ALL is 2,500 IU/m^2 every two weeks intramuscular
           (IM)/intravenous (IV). IM dosing of 2,000 IU/m^2 every two weeks has been studied in a
           phase I protocol with various solid tumors.

        -  Demonstration of safety and anti-angiogenic activity will lead to combination studies.

      Primary Objectives:

        -  To preliminarily evaluate the anti-tumor activity of pegaspargase, 2,000 IU/ m^2 every
           two weeks intravenous (IV) (or intramuscular (IM)) and explore associations with
           toxicity and clinical outcome.

        -  To evaluate the safety of pegaspargase in patients with recurrent or refractory ovarian,
           fallopian tube, and/or primary peritoneal cancer.

      Secondary Objectives:

        -  To explore changes in circulating angiogenic cytokines after treatment with
           pegaspargase.

        -  To measure apoptosis and proliferation in tumor (or malignant effusion) by protein array
           before and during therapy.

        -  To evaluate changes in tumor vascularity using dynamic contrast enhanced (DCE) magnetic
           resonance imaging (MRI).

      Eligibility:

        -  Women with epithelial ovarian cancer, fallopian tube cancer, and/or primary peritoneal
           cancer that is persistent, relapsed and/or refractory to prior therapy.

        -  There is no limit to number of prior treatment regimens. Patients may not have
           previously received L-ASP.

        -  Women must have disease amenable to biopsy or malignant effusions (pleural effusion or
           ascites) that may be serially tapped.

        -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2.

        -  Evidence of adequate end organ function and normal coagulation parameters (prothrombin
           time (PT), activated partial thromboplastin time (aPTT)).

      Design:

        -  Women will receive 2,000 IU/m^2 of pegaspargase intravenously every two weeks in 28-day
           cycles until disease progression, excessive toxicity, or withdrawal from study.

        -  Biopsy of tumor and dynamic contrast-enhanced-magnetic resonance imaging (MRI) will be
           performed prior to starting pegaspargase (mandatory) and after 6 weeks of treatment
           (optional).

        -  Clinical outcome will be measured and correlated with biological endpoints.

        -  Research blood samples will be taken to assess changes in serum vascular endothelial
           growth factor (VEGF), interleukin-6 (IL6), and interleukin-8 (IL8).

        -  Blood will be collected to evaluate circulating endothelial cells.

        -  Patients will be seen in clinic every 4 weeks and outcome measured every other cycle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Month Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients able to attain a 6 month progression free survival. Progressive disease is defined as &gt;20% increase in the sum of the longest diameter of all target lesions, or the unequivocal increase in size of non-measurable lesions agreed upon by two investigators, or the appearance of new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.</measure>
    <time_frame>11 months, 25 days</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Primary Peritoneal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pegaspargase in women with cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated L-Asparaginase</intervention_name>
    <description>Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks</description>
    <arm_group_label>Pegaspargase in women with cancer</arm_group_label>
    <other_name>Oncaspar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  All patients 18 years and older with epithelial ovarian, fallopian tube, or primary
             peritoneal cancer that is persistent, relapsed or refractory to prior standard
             platinum and taxane-based therapy will be eligible. Tumor histology must be reviewed
             and confirmed by the National Cancer Institute (NCI) Laboratory of Pathology.
             Recurrent ovarian cancer is not a curable tumor. Patients who are platinum-sensitive
             and who, upon detailed informed consent, wish to consider this experimental regimen,
             will be considered.

          -  All patients must have measurable disease by Response Evaluation Criteria in Solid
             Tumors (RECIST) criteria. A sentinel lesion adequate for core biopsy through
             percutaneous route is ideal but not mandatory. Patients with a malignant pleural
             effusion or malignant ascites will be allowed to undergo a paracentesis or
             thoracentesis rather than core needle biopsy if the procedure may be performed safely.

          -  Patients must have a performance status of Eastern Cooperative Oncology Group (ECOG) =
             0, 1, 2

          -  Patients must have adequate end organ function:

               -  Absolute neutrophil count (ANC) greater than or equal to 1500/ mm^3

               -  Platelets greater than or equal to 100,000/ mm^3

               -  Serum creatinine less than or equal to 1.5 mg/dL, or if low, creatinine clearance
                  greater than or equal to 60 mL/min

               -  Total bilirubin less than or equal to 1.5 times the ULN (upper limit of normal)
                  unless a history of Gilbert's disease.

               -  Lipase and amylase less than or equal to 1.5 times the ULN

               -  Transaminases (aspartate aminotransferase (AST), alanine aminotransferase (ALT))
                  less than or equal to 2.5 times the ULN

               -  Fibrinogen greater than or equal to 0.75 times the LLN

               -  Prothrombin time (PT), partial thromboplastin time (PTT), and International
                  Normalized Ratio (INR) less than or equal to 1.5 times the ULN. Coagulation
                  parameters must be drawn peripherally.

          -  Patients must be at least 4 weeks from previous therapy (chemotherapy, hormonal
             therapy, and radiation therapy, alternative therapy, investigational agents, or a
             major surgical procedure). Patients must be 6 weeks from carboplatin- or mitomycin
             C-containing therapy. Exceptions: Raloxifene will be allowed for bone health and
             bisphosphonate therapy will be allowed for the rare situation of bone metastasis.

          -  There is no limit to the number of prior regimens patients may have received for the
             treatment of ovarian cancer.

          -  Patients must have recovered from any toxicity related to prior cancer therapy to
             Common Terminology Criteria for Adverse Events (CTCAE) grade 1, except for stable
             peripheral neuropathy, which must have recovered to grade 2 or better, and grade 2
             total white blood cell count when ANC is greater than or equal to 1500 (alopecia and
             hypertension exempted).

          -  Women of childbearing potential must agree to use adequate barrier contraception
             (interaction with oral contraceptives is unknown) prior to study entry, during therapy
             and for 3 months after completion of therapy and must have a negative pregnancy test.

          -  Patients must be able to give written informed consent.

        EXCLUSION CRITERIA:

          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which
             in the Investigator's opinion makes it unsafe for the patient to participate in the
             trial or which would jeopardize compliance with the protocol.

          -  Evidence of central nervous system (CNS) involvement. Patients with abnormal clinical
             exam or history will require a head computed tomography (CT) or magnetic resonance
             imaging (MRI).

          -  History of clinically symptomatic pancreatitis within the six months prior to
             enrollment.

          -  History of prior exposure to any formulation of L-asparaginase.

          -  Patients with a history of deep venous thrombosis or pulmonary embolism within the
             past 3 months, or pulmonary embolism within the past 6 months, history of recurrent
             clot or pulmonary embolism (PE), or those patients requiring ongoing full dose
             anticoagulation will be ineligible. Line prophylaxis with 1 mg warfarin daily will be
             allowed.

          -  Patients with active infection will not be eligible, but may become eligible once
             infection has resolved and they are at least 7 days from completion of antibiotics.

          -  Women who are pregnant and women actively breast-feeding will be excluded.

          -  Previous or current malignancies within the last 5 years, with the exception of
             cervical carcinoma in situ curatively treated, ductal or lobular carcinoma in situ
             curatively treated and without ongoing therapeutic intervention, and nonmelanomatous
             skin cancers curatively treated.

          -  No concomitant use of complementary or alternative medication or other agents
             (investigational or anti-cancer agents) will be allowed without approval of a
             principal investigator (PI) or associate investigator (AI). Every effort will be made
             to maximize patient safety and minimize changes in chronic medications.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elise C Kohn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2010-C-0028.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001 May 17;411(6835):375-9. Review.</citation>
    <PMID>11357145</PMID>
  </reference>
  <reference>
    <citation>Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res. 1999 Mar;5(3):587-91.</citation>
    <PMID>10100710</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <results_first_submitted>August 13, 2012</results_first_submitted>
  <results_first_submitted_qc>August 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2012</results_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>Elise C. Kohn, M.D./National Cancer Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <keyword>Primary Peritoneal Cancer</keyword>
  <keyword>Relapsed or Refractory</keyword>
  <keyword>Pegaspargase</keyword>
  <keyword>Pegylated L-Asparaginase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pegaspargase in Women With Cancer</title>
          <description>Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegaspargase in Women With Cancer</title>
          <description>Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6 Month Progression Free Survival</title>
        <description>Proportion of patients able to attain a 6 month progression free survival. Progressive disease is defined as &gt;20% increase in the sum of the longest diameter of all target lesions, or the unequivocal increase in size of non-measurable lesions agreed upon by two investigators, or the appearance of new lesions.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegaspargase in Women With Cancer</title>
            <description>Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Progression Free Survival</title>
          <description>Proportion of patients able to attain a 6 month progression free survival. Progressive disease is defined as &gt;20% increase in the sum of the longest diameter of all target lesions, or the unequivocal increase in size of non-measurable lesions agreed upon by two investigators, or the appearance of new lesions.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
        <time_frame>11 months, 25 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegaspargase in Women With Cancer</title>
            <description>Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pegaspargase in Women With Cancer</title>
          <description>Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify (Urgency bowel movement)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Investigations-Other, specify (PT, high)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elise Kohn, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-9336</phone>
      <email>kohne@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

